Coherus BioSciences Inc at Bank of America Global Healthcare Conference Transcript
Yes. My name is Bhavin Patel, one of the biopharma analysts here at BofA. I'm here with Denny, CEO of Coherus.
Questions & Answers
So to jump right into the Q&A. You reported 1Q, and the stock is down to about $5 a share trading at 52-week lows. And I wanted to get your thoughts on what do you think is the reason? And is it an overreaction to the maybe miss on UDENYCA?
Well, sure. I think it's a little overdone. Frankly, I've had better weeks than this week. But I think you have to put it in perspective in the long-term view of the company. Q1 was the last quarter in which we had only one undifferentiated presentation for UDENYCA. So this is a market in which we've said many times there was additional competitors and entrants. And that put significant pressure on competitive pricing dynamics and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |